Pimavanserin Snag: FDA Rejects Acadia’s Dementia Psychosis Drug
By
Alexandra Marvar
| April 5th, 2021
Due to apparent “deficiencies” in trial data, the FDA has rejected a request to approve Acadia Pharmaceutical’s application for the repurposing of Parkinson’s drug…